Skip to main content
. 2015 Oct;185(10):2790–2804. doi: 10.1016/j.ajpath.2015.06.007

Figure 7.

Figure 7

Nherf2−/− mice have attenuated diarrhea in DSS- and TNBS-induced colitis. A: Experimental design of DSS treatment in Nherf2+/+ and Nherf2−/− mice for a period of 7 days. Line graph shows the mouse total body weight measurements over a period of 7 days for the experimental groups: Nherf2+/+ ± DSS treatment and Nherf2−/− ± DSS treatment. B: Experimental design of DSS treatment in Nherf2+/+ and Nherf2−/− mice for a period of 7 days. Line graph shows the mouse total body weight measurements over a period of 3 days for the experimental groups: Nherf2+/+ ± TNBS treatment and Nherf2−/− ± TNBS treatment. C: Representative exteriorized mice colons of the various treatment groups. Arrows show the extent of fluid accumulation in the colon. D: Bar graphs show the assessments of various disease variables of DSS-induced colitis, including stool score and wet/dry weight ratio of the fecal pellets in Nherf2+/+ and Nherf2−/− mice. E: Bar graphs show the measured stool score and wet/dry weight ratio of the fecal pellets in TNBS-treated Nherf2+/+ and Nherf2−/− mice. F: Schematic representation of CFTR and iNOS interaction in the gut epithelia and the associated molecular machinery in inflammatory bowel disorder-affected gut epithelia. Data are expressed as means ± SEM. n = 4 experimental groups (A and B); n = 3 to 4 mice per group (A); n = 5 to 8 mice per TNBS group (B); n = 3 mice per control group with no DSS treatment (D); n = 8 to 10 mice per DSS treatment group (D); n = 8 to 10 mice per TNBS treatment group (E). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 calculated with t-test. Significance of intergroup variance was evaluated with one-way analysis of variance for animal experiments. CFTR, cystic fibrosis transmembrane-conductance regulator; DSS, dextran sodium sulfate; iNOS, inducible nitric oxide synthase; NHERF2, Na+/H+ exchanger regulatory factor 2; sGC, soluble guanylate cyclase; TNBS, 2,4,6-trinitrobenzenesulfonic.